Back to mobile site

Cantor Fitzgerald Reiterates Overweight Rating, $31 Price Target on EyePoint Pharmaceuticals, Inc. (EYPT)

October 13, 2022 6:05 AM EDT Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $31.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login